Yıl: 2020 Cilt: 26 Sayı: 1 Sayfa Aralığı: 47 - 52 Metin Dili: İngilizce DOI: 10.5152/eurjther.2020.19132 İndeks Tarihi: 08-12-2020

Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes

Öz:
Objective: Diabetes mellitus (DM) is a common disorder that causes undesirable medical and economic consequences. A simple, reliable, and validated self-report instrument could provide a better understanding of non-adherence to treatment and may help identify new treatment modalities. Thus, the eight-item Morisky Medication Adherence Scale (MMAS-8) was developed. The aim of this study was to evaluate the validity and reliability of the MMAS-8 among Turkish diabetes mellitus patients. Methods: This cross-sectional descriptive study enrolled 199 patients. The Turkish translation of the Morisky-8 item scale consisted of forward translation, reconciliation, back translation, back translation review, developer review, pilot testing, and final translation. Results: Cronbach’s alpha test of internal consistency was calculated at alpha=0.890 for the eight items of the MMAS-8 scale. CFA demonstrated the scale fitted CMIN/DF=1.194, GFI=0.970, CFI=0.995, RMSEA=0.031. Poor glycemic control (HbA1c<7) was significantly higher in the low-adherence group than in the high- and medium-adherence groups (p=0.001, LR=21.79). Approximately 94% of the low-adherence group patients were in the poor glycemic control group. Conclusion: The MMAS-8 Turkish version was found to be a valid and reliable scale in diabetic patients. This self-reported scale could function as a screening tool in busy clinics to identify patients with low adherence to medication treatment. Moreover, the MMAS-8 Turkish version could help improve adherence and develop new treatment strategies.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd, Sheree, Dunning T, et al. Diabetes Atlas. Guariguata L, Nolan T, Beagley J, Linnenkamp U, Jacqmain O, editors. International Diabetes Federation. 6th edi-tion. Basel: Faculty of Health School of Nursing and Midwifery Cen-tre for Quality and Patient Safety Research; 2014.p.34-6.
  • 2. Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabe-tes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas) 2019; 29: 55. [CrossRef ]
  • 3. Jacobs E, Hoyer A, Brinks R, Icks A, Kuss O, Rathmann W. Healthcare costs of Type 2 diabetes in Germany. Diabet Med 2017; 34: 855-61. [CrossRef ]
  • 4. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97. [CrossRef ]
  • 5. Doggrell SA, Chan V. Adherence to insulin treatment in diabetes: can it be improved? J Diabetes 2015; 7: 315-21. [CrossRef ]
  • 6. Hernandez-Ronquillo L, Téllez-Zenteno JF, Garduño-Espinosa J, González-Acevez E. Factors associated with therapy noncompliance in type-2 diabetes patients. Salud Pública de Méx 2003; 45: 191-7. [CrossRef ]
  • 7. Rubin RR. Adherence to pharmacologic therapy in patients with Type 2 diabetes mellitus. Am J Med 2005; 118(Suppl 5A): 27S-34S. [CrossRef ]
  • 8. Rhee MK, Slocum W, Ziemer DC, Culler SD, Cook CB, El-Kebbi IM, et al. Patient adherence improves glycemic control. Diabetes Educ 2005; 31: 240-50.[CrossRef ]
  • 9. Krapek K, King K, Warren SS, George KG, Caputo DA, Miehelich K, et al. Medication adherence and associated hemoglobin A1C in type 2 diabetes. Ann Pharmacother 2004; 38: 1357-62. [CrossRef ]
  • 10. Kuritzky L. Managing type 2 diabetes in the primary care setting: beyond glucocentricity. Am J Med Sci 2010; 340: 133-43. [CrossRef ]
  • 11. Adisa R, Olajide OO, Fakeye TO. Social support, treatment adherence and outcome among hypertensive and type 2 diabetes patients in ambulatory care settings in Southwestern Nigeria. Ghana Med J 2017; 51: 64-77.
  • 12. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adher-ence to treatment three decades of research: a comprehensive re-view. J Clinical Pharm Ther 2001; 26: 331-42.[CrossRef ]
  • 13. Furukawa S, Kumagi T, Miyake T, Ueda T, Niiya T, Nishino K, et al. Sui-cide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature. Endocr J 2012; 59: 329-33. [CrossRef ]
  • 14. Surendiran A, Pradhan SC, Agrawal A, Subrahmanyam DKS, Rjan S, Anichavezhi D, et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol 2011; 67: 797-801. [CrossRef ]
  • 15. Hawkins JM. Type 2 diabetes self-management in non-hispanic black men: a current state of the literature. Curr Diab Rep 2019; 19: 10.[CrossRef ]
  • 16. Garfield S, Clifford S, Eliasson L, Barber N, Willson A. Suitability of mea-sures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol 2011; 11: 149. [CrossRef ]
  • 17. Morisky DE and DiMatteo MR. Improving the measurement of self-reported medication nonadherence: response to authors J Clin Epidemiol 2011; 64: 255-7. [CrossRef ]
  • 18. Sakthong P, Chabunthom R, Charoenvisuthiwongs R. Psychometric properties of the Thai version of the 8-item Morisky Medication Ad-herence Scale in patients with type 2 diabetes. Ann Pharmacother 2009; 43: 950-7.[CrossRef ]
  • 19. Al-Qazaz HK, Hassali MA, Shafie AA, Shafie AA, Sulaiman SA, et al. The eight-item Morisky Medication Adherence Scale MMAS: transla-tion and validation of the Malaysian version. Diabetes Res Clin Pract 2010; 90: 216-21. [CrossRef ]
  • 20. Satman I, Ömer B, Tütüncü Y, Kalaca S, Gedik S, Dinççay N, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28: 169-80. [CrossRef ]
  • 21. Hogarty KY, Hines CV, Kromrey JD, Ferron JM, Mumford KR. The qual-ity of factor solutions in exploratory factor analysis: the influence of sample size, communality, and over determination. Educ Psychol Meas 2005; 65: 202-26.[CrossRef ]
  • 22. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in se-niors with hypertension. Am J Manag Care 2009; 15: 59-66.
  • 23. Hu, L.T. and Bentler, P.M. Cutoff criteria for fit ındexes in covariance structure analysis: conventional criteria. versus new alternatives. Struct Equ Modeling 1999; 6: 1-55. [CrossRef ]
  • 24. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sher-win R, et al. American Diabetes Association, European Association for study of diabetes. medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjust-ment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2009; 32: 193-203.[CrossRef ]
  • 25. Tzeng JI, Chang CC, Chang HJ, Lin CC. Assessing analgesic regimen ad-herence with the Morisky Medication Adherence Measure for Taiwanese patients with cancer pain. J Pain Symptom Manage 2008; 36: 157-66. [CrossRef ]
  • 26. Lee WY, Ahn J, Kim JH, Hong YP, Hong SK, Kim YT, et al. Reliability and validity of a self reported measure of medication adherence in patients with type 2 diabetes mellitus in Korea. J. Int Med Res 2013; 41: 1098-110. [CrossRef ]
  • 27. Morisky DE, Ang A, Krousel-Wood M, Ward, HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hy-pertens 2008; 10: 348-54.[CrossRef ]
  • 29. Okello S, Nasasira B, Muiru AN, Muyingo A. Validity and reliability of a self-reported measure of antihypertensive medication adherence in Uganda. PLoS One 2016; 11: e0158499 [CrossRef ]
  • 30. Tandon S, Chew M, Eklu-Gadegbeku CK, Shermock KM, Morisky DE. Validation and psychometric properties of the 8-item Morisky Medication Adherence Scale (MMAS-8) in Type 2 diabetes patients in sub-Saharan Africa. Diabetes Res Clin Pract 2015; 110: 129-36. [CrossRef ]
  • 31. Moharamzad Y, Saadat H, Nakhjavan Shahraki B, Rai A, Saadat Z, Aerab-Sheibani H, et al. Validation of the Persian version of the 8-Item Morisky Medication Adherence Scale (MMAS-8) in Iranian hypertensive patients. Glob J Health Sci 2015; 7: 173-83. [CrossRef ]
  • 32. de Oliveira-Filho AD, Morisky DE, Neves SJ, Costa FA, de Lyra DP Jr. The 8-item Morisky Medication Adherence Scale: validation of a Brazilian-Portuguese version in hypertensive adults. Res Social Adm Pharm 2014; 10: 554-61. [CrossRef ]
  • 33. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. 4th ed. Oxford: Oxford Univer-sity Press; 2008.p.167-327.
  • 34. Satman I, Yilmaz T, Sengul A, Salman S, Salman F, Uygur S, et al. Pop-ulation-based study of diabetes and risk characteristics in Turkey: Results of the Turkish diabetes epidemiology study (TURDEP). Dia-betes Care 2002; 25: 1551-6.[CrossRef ]
APA SAYİNER Z, SAVAŞ E, KUL S, MORİSKY D (2020). Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes. , 47 - 52. 10.5152/eurjther.2020.19132
Chicago SAYİNER Zeynel Abidin,SAVAŞ Esen,KUL Seval,MORİSKY Donald E. Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes. (2020): 47 - 52. 10.5152/eurjther.2020.19132
MLA SAYİNER Zeynel Abidin,SAVAŞ Esen,KUL Seval,MORİSKY Donald E. Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes. , 2020, ss.47 - 52. 10.5152/eurjther.2020.19132
AMA SAYİNER Z,SAVAŞ E,KUL S,MORİSKY D Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes. . 2020; 47 - 52. 10.5152/eurjther.2020.19132
Vancouver SAYİNER Z,SAVAŞ E,KUL S,MORİSKY D Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes. . 2020; 47 - 52. 10.5152/eurjther.2020.19132
IEEE SAYİNER Z,SAVAŞ E,KUL S,MORİSKY D "Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes." , ss.47 - 52, 2020. 10.5152/eurjther.2020.19132
ISNAD SAYİNER, Zeynel Abidin vd. "Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes". (2020), 47-52. https://doi.org/10.5152/eurjther.2020.19132
APA SAYİNER Z, SAVAŞ E, KUL S, MORİSKY D (2020). Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes. European Journal of Therapeutics, 26(1), 47 - 52. 10.5152/eurjther.2020.19132
Chicago SAYİNER Zeynel Abidin,SAVAŞ Esen,KUL Seval,MORİSKY Donald E. Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes. European Journal of Therapeutics 26, no.1 (2020): 47 - 52. 10.5152/eurjther.2020.19132
MLA SAYİNER Zeynel Abidin,SAVAŞ Esen,KUL Seval,MORİSKY Donald E. Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes. European Journal of Therapeutics, vol.26, no.1, 2020, ss.47 - 52. 10.5152/eurjther.2020.19132
AMA SAYİNER Z,SAVAŞ E,KUL S,MORİSKY D Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes. European Journal of Therapeutics. 2020; 26(1): 47 - 52. 10.5152/eurjther.2020.19132
Vancouver SAYİNER Z,SAVAŞ E,KUL S,MORİSKY D Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes. European Journal of Therapeutics. 2020; 26(1): 47 - 52. 10.5152/eurjther.2020.19132
IEEE SAYİNER Z,SAVAŞ E,KUL S,MORİSKY D "Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes." European Journal of Therapeutics, 26, ss.47 - 52, 2020. 10.5152/eurjther.2020.19132
ISNAD SAYİNER, Zeynel Abidin vd. "Validity and Reliability of the Turkish Version of the 8-Item Morisky Medication Adherence Scale in Patients With Type 2 Diabetes". European Journal of Therapeutics 26/1 (2020), 47-52. https://doi.org/10.5152/eurjther.2020.19132